AQR Capital Management LLC Decreases Position in The Cooper Companies, Inc. $COO

Key Points

• AQR Capital Management LLC significantly reduced its stake in The Cooper Companies, Inc. by 49.5%, now owning 124,205 shares valued at approximately $10.4 million after selling over 121,000 shares.
• Several institutional investors increased their holdings, with Amundi raising its position by 6.9% and Twin Tree Management LP increasing by a staggering 669.1%.
• Cooper Companies posted earnings of $1.10 per share for the recent quarter, surpassing analyst expectations and showing a 5.7% revenue increase year-over-year.

AQR Capital Management LLC lowered its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 49.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,205 shares of the medical device company's stock after selling 121,680 shares during the quarter. AQR Capital Management LLC owned about 0.06% of Cooper Companies worth $10,429,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Zions Bancorporation National Association UT purchased a new stake in Cooper Companies in the first quarter valued at approximately $33,000. City Holding Co. purchased a new stake in Cooper Companies in the first quarter valued at approximately $34,000. GKV Capital Management Co. Inc. purchased a new stake in Cooper Companies in the first quarter valued at approximately $40,000. Larson Financial Group LLC boosted its position in Cooper Companies by 1,071.0% in the first quarter. Larson Financial Group LLC now owns 726 shares of the medical device company's stock valued at $61,000 after buying an additional 664 shares during the last quarter. Finally, HM Payson & Co. boosted its position in Cooper Companies by 147.4% in the first quarter. HM Payson & Co. now owns 893 shares of the medical device company's stock valued at $75,000 after buying an additional 532 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company's stock.

Cooper Companies Trading Down 2.6%

Shares of NASDAQ:COO traded down $1.78 during midday trading on Friday, reaching $66.68. 3,147,814 shares of the company's stock were exchanged, compared to its average volume of 3,235,975. The firm's 50 day simple moving average is $71.53 and its two-hundred day simple moving average is $76.00. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The stock has a market cap of $13.26 billion, a price-to-earnings ratio of 32.85, a P/E/G ratio of 1.80 and a beta of 0.97. The Cooper Companies, Inc. has a fifty-two week low of $61.78 and a fifty-two week high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.03. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company's quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the company earned $0.96 EPS. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, sell-side analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

COO has been the topic of several recent research reports. Loop Capital set a $100.00 price objective on Cooper Companies in a research report on Tuesday, June 17th. Robert W. Baird lowered their price objective on Cooper Companies from $97.00 to $85.00 and set an "outperform" rating on the stock in a research report on Thursday, August 28th. Stifel Nicolaus lowered their price objective on Cooper Companies from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Thursday, August 28th. BNP Paribas Exane upgraded Cooper Companies from a "neutral" rating to an "outperform" rating and set a $92.00 price objective on the stock in a research report on Tuesday, July 22nd. Finally, Needham & Company LLC restated a "buy" rating and issued a $94.00 price objective on shares of Cooper Companies in a research report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Cooper Companies has a consensus rating of "Moderate Buy" and an average price target of $86.64.

Insider Transactions at Cooper Companies

In related news, COO Gerard H. Warner III acquired 1,450 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was acquired at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the purchase, the chief operating officer owned 18,319 shares of the company's stock, valued at $1,268,224.37. This represents a 8.60% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride acquired 3,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was bought at an average price of $65.04 per share, with a total value of $195,120.00. Following the purchase, the chief operating officer directly owned 63,120 shares in the company, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 15,975 shares of company stock valued at $1,079,566. 1.98% of the stock is owned by insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.